In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Brooke DirvinColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY USA 10032.ORCID 0000-0002-3948-1548 Heeju NohDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA 10032.ORCID 0000-0002-9299-4852 Lorenzo Tomassoni *Department of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA 10032.ORCID 0000-0002-7720-9166 Danting CaoColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY USA 10032.
Yizhuo ZhouColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY USA 10032.
Xiangyi KeColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY USA 10032.
Jun QianColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY USA 10032.
Sonia JangraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-3156-3132 Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-6551-1827 Charles KaranDepartment of Systems Biology, J.P. Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, NY, USA 10032.
Andrea CalifanoDepartment of Systems Biology, J.P. Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, NY, USA 10032.ORCID 0000-0003-4742-3679 Wellington V CardosoColumbia Center for Human Development, Columbia University Irving Medical Center, New York, NY USA 10032.ORCID 0000-0002-8868-9716 Funding
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MMechanisms Controlling Expansion and Lineage Specification of Airway Progenitors in Development and DiseaseR35HL135834 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CARDOSO, WELLINGTON V. · 2017 to 2023
$6.7MCombined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9MGenetic Approaches to Development and DiseaseT32GM141882 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERCHOWITZ, LUKE E, SHIRASU-HIZA, MICHELE M · 2021 to 2025
$2.1MHigh-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0MExperimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3MStorage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600kNCI NIH HHS R35 CA197745NHLBI NIH HHS R35 HL135834NIAID NIH HHS R01 AI160706NIAID NIH HHS U19 AI135972NIDDK NIH HHS R01 DK130425NIGMS NIH HHS T32 GM141882NIH HHS S10 OD012351NIH HHS S10 OD021764
6 · The paper itselfAbstract
Although the impact of SARS-CoV-2 in the lung has been extensively studied, the molecular regulators and targets of the host-cell programs hijacked by the virus in distinct human airway epithelial cell populations remain poorly understood. This is in part ascribed to the use of nonprimary cell systems, overreliance on single-cell gene expression profiling that does not ultimately reflect protein activity, and bias toward the downstream effects rather than their mechanistic determinants. Here we address these issues by network-based analysis of single cell transcriptomic profiles of pathophysiologically relevant human adult basal, ciliated and secretory cells to identify master regulator (MR) protein modules controlling their SARS-CoV-2-mediated reprogramming. This uncovered chromatin remodeling, endosomal sorting, ubiquitin pathways, as well as proviral factors identified by CRISPR analyses as components of the host response collectively or selectively activated in these cells. Large-scale perturbation assays, using a clinically relevant drug library, identified 11 drugs able to invert the entire MR signature activated by SARS-CoV-2 in these cell types. Leveraging MR analysis and perturbational profiles of human primary cells represents a novel mechanism-based approach and resource that can be directly generalized to interrogate signatures of other airway conditions for drug prioritization.
Indexed as
air-liquid-interfaceairway epitheliumdrug screeningmetaVIPERSARS-CoV-2single-cell RNA seqViroTreatvirus-host interactions
Identifiers
PMID39464067
PMCPMC11507692
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390